FDA Warning On Data Integrity: “Sometimes Lawyers Become Too Clever For Their Own Good”
This article was originally published in The Rose Sheet
Executive Summary
How companies handle manufacturing troubles may be more important to the agency than that they happen, top FDA officials indicate, warning that a damaged relationship can affect all of a firm’s interactions with FDA.
You may also be interested in...
FDA’s Call for Quality: Revamped GMP Initiative Stresses Cost Savings
FDA is kicking off phase two of its 21st Century GMP initiative using new authorities and funding under the FDA Safety & Innovation Act. To encourage investment in quality manufacturing systems, the agency is highlighting the cost savings seen by early adopters of quality systems..
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.
Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests
The rulemaking is supposed to formalize the Patent Trial and Appeal Board process, which has been in an interim status since a Supreme Court decision, giving manufacturers more ability to request oversight of the decisions.